Journal
GYNECOLOGIC ONCOLOGY
Volume 156, Issue 1, Pages 251-259Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ygyno.2019.11.020
Keywords
Endometrial cancer; Pre-clinical models; Patient derived explant; Tumour heterogeneity; Tumour microenvironment
Categories
Funding
- University of Leicester
- MRC Toxicology Unit
- Cancer Research UK Therapeutic Discovery Laboratories
- LifeArc
- CRUK-NIHR Leicester Experimental Cancer Medicine Centre [C10604/A25151]
- Hope Against Cancer
- Breast Cancer Now's Catalyst Programme - Pfizer [2017NOVPCC1066]
- MRC [MC_PC_15045, MC_PC_16051, MC_UU_00025/4, MC_PC_14117] Funding Source: UKRI
Ask authors/readers for more resources
The majority of endometrial cancers are detected early with a favourable prognosis. However, for patients with advanced disease, chemotherapy response rates and overall survival remains poor. The endometrial cancer population is typically elderly with multiple co-morbidities and aggressive cytotoxic therapy may be hazardous. Therefore, there is an urgent need to define optimal treatment strategies for advanced and recurrent disease and personalise therapy based on individual tumour and patient characteristics. Three-dimensional (3D) models that preserve the tumour microenvironment and tumour-stromal interactions are increasingly important for translational research with the advent of immunotherapy and molecularly targeted agents. 3D patient-relevant pre-clinical models in endometrial cancer include spheroids, patient-derived organoids, microfluidic systems, patient-derived xenografts and patient-derived explants. Here we present a review of available 3D modelling systems in endometrial cancers, highlighting their current use, advantages, disadvantages and applications to translational research with a focus on the power of the patient-derived explant platform. (C) 2019 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available